Physician
Gastroenterology
Dr. Laurence J. Miller, MD
|
|
Give Review
Dr. Laurence J. Miller works in the field of Gastroenterology. He attended Jefferson Medical College. He received awards:"Elected Member" and "Super Doctor". Doctor Laurence J. Miller, MD is a published MD. He published 101 publications, including: 'Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding.' Laurence J. Miller accepts Medicare.
Publications
- Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding.
- A type 1 CCK receptor mutant that mimics the dysfunction observed for wild type receptor in a high cholesterol environment.
- Structure and function of Norrin in assembly and activation of a Frizzled 4-Lrp5/6 complex.
- Direct demonstration of unique mode of natural peptide binding to the type 2 cholecystokinin receptor using photoaffinity labeling.
- Minireview: Signal Bias, Allosterism, and Polymorphic Variation at the GLP-1R: Implications for Drug Discovery.
- Structural and functional insights into the juxtamembranous amino-terminal tail and extracellular loop regions of class B GPCRs.
- Molecular basis for benzodiazepine agonist action at the type 1 cholecystokinin receptor.
- Membrane Cholesterol Affects Stimulus-Activity Coupling in Type 1, but not Type 2, CCK Receptors: Use of Cell Lines with Elevated Cholesterol.
- The orthosteric agonist-binding pocket in the prototypic class B G-protein-coupled secretin receptor.
- Mapping spatial approximations between the amino terminus of secretin and each of the extracellular loops of its receptor using cysteine trapping.
- Insights into the impact of phenolic residue incorporation at each position along secretin for receptor binding and biological activity.
- The second extracellular loop of the human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation.
- The second extracellular loop of the human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function.
- Ligand-induced internalization of the type 1 cholecystokinin receptor independent of recognized signaling activity.
- Site of action of a pentapeptide agonist at the glucagon-like peptide-1 receptor. Insight into a small molecule agonist-binding pocket.
- Differential sensitivity of types 1 and 2 cholecystokinin receptors to membrane cholesterol.
- Quiescin Sulfhydryl Oxidase 1 Promotes Invasion of Pancreatic Tumor cells Mediated by Matrix Metalloproteinases.
- Lactam Constraints Provide Insights into the Receptor-Bound Conformation of Secretin and Stabilize a Receptor Antagonist.
- Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation.
- Molecular basis of secretin docking to its intact receptor using multiple photolabile probes distributed throughout the pharmacophore.
- Refinement of Glucagon-like Peptide 1 Docking to Its Intact Receptor Using Mid-region Photolabile Probes and Molecular Modeling.
- Ligand Binding and Activation of the Secretin Receptor, a Prototypic Family B G Protein-Coupled Receptor.
- Importance of Each Residue within Secretin for Receptor Binding and Biological Activity.
- Fluorescence Polarization Screening for Allosteric Small Molecule Ligands of the Cholecystokinin Receptor.
- Characterization of alternative spliceoforms and the RNA splicing machinery in pancreatic cancer.
- Functional and structural diversification of the Anguimorpha lizard venom system.
- Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: i...
- Spatial approximations between residues 6 and 12 in the amino-terminal region of glucagon-like peptide 1 and its receptor: a region critical for biological activity.
- Role of N-linked glycosylation in biosynthesis, trafficking, and function of the human glucagon-like peptide 1 receptor.
- Refinement of the pharmacophore of an agonist ligand of the secretin receptor using conformationally constrained cyclic hexapeptides.
- Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.
- Dimeric arrangement of the parathyroid hormone receptor and a structural mechanism for ligand-induced dissociation.
- Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization.
- Risk factors for pancreatic adenocarcinoma and prospects for screening.
- Secretin occupies a single protomer of the homodimeric secretin receptor complex: insights from photoaffinity labeling studies using dual sites of covalent attachment.
- Molecular basis of association of receptor activity-modifying protein 3 with the family B G protein-coupled secretin receptor.
- Molecular basis of glucagon-like peptide 1 docking to its intact receptor studied with carboxyl-terminal photolabile probes.
- Juxtamembranous region of the amino terminus of the family B G protein-coupled calcitonin receptor plays a critical role in small-molecule agonist action.
- Functional importance of a structurally distinct homodimeric complex of the family B G protein-coupled secretin receptor.
- Alternative splicing of pre-mRNA in cancer: focus on G protein-coupled peptide hormone receptors.
- Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling.
- Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors.
- Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands.
- Application of fluorescence resonance energy transfer techniques to establish ligand-receptor orientation.
- Use of fluorescence indicators in receptor ligands.
- Homology modeling of GPCRs.
- Monitoring the state of cholecystokinin receptor oligomerization after ligand binding using decay of time-resolved fluorescence anisotropy.
- G protein-coupled receptor structures, molecular associations, and modes of regulation.
- Exploration of the endogenous agonist mechanism for activation of secretin and VPAC1 receptors using synthetic glycosylated peptides.
- Informed development of drugs acting at family B G protein-coupled receptors.
- Pattern of intra-family hetero-oligomerization involving the G-protein-coupled secretin receptor.
- Use of multidimensional fluorescence resonance energy transfer to establish the orientation of cholecystokinin docked at the type A cholecystokinin receptor.
- Effects of cholecystokinin-58 on type 1 cholecystokinin receptor function and regulation.
- Spatial approximation between secretin residue five and the third extracellular loop of its receptor provides new insight into the molecular basis of natural agonist b...
- Effects of cholecystokinin-58 on Type 1 cholecystokinin receptor function and regulation. Receptor binding, activation, internalization and oligomerization.
- The micelle-associated 3D structures of Boc-Y(SO3)-Nle-G-W-Nle-D-2-phenylethylester (JMV-180) and CCK-8(s) share conformational elements of a calculated CCK1 receptor-...
- Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors.
- Wild-type and splice-variant secretin receptors in lung cancer: overexpression in carcinoid tumors and peritumoral lung tissue.
- Extent and diversity of human alternative splicing established by complementary database annotation and microarray analysis.
- Mutational analysis of predicted intracellular loop domains of human motilin receptor.
- Distinctive heavy metal composition of pancreatic juice in patients with pancreatic carcinoma.
- New technology, new complications: pancreatitis complicating double-balloon enteroscopy.
- Fluorescence resonance energy transfer analysis of secretin docking to its receptor: mapping distances between residues distributed throughout the ligand pharmacophore...
- Transmembrane segment IV contributes a functionally important interface for oligomerization of the Class II G protein-coupled secretin receptor.
- A novel secretin receptor splice variant potentially useful for early diagnosis of pancreatic carcinoma.
- Mapping the architecture of secretin receptors with intramolecular fluorescence resonance energy transfer using acousto-optic tunable filter-based spectral imaging.
- Molecular approximations between residues 21 and 23 of secretin and its receptor: development of a model for peptide docking with the amino terminus of the secretin re...
- Role of lysine187 within the second extracellular loop of the type A cholecystokinin receptor in agonist-induced activation. Use of complementary charge-reversal mutag...
- Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreati...
- Transmembrane segment peptides can disrupt cholecystokinin receptor oligomerization without affecting receptor function.
- Fluorescent indicators distributed throughout the pharmacophore of cholecystokinin provide insights into distinct modes of binding and activation of type A and B chole...
- Secretin receptor oligomers form intracellularly during maturation through receptor core domains.
- Use of photoaffinity labeling to understand the molecular basis of ligand binding to the secretin receptor.
- Molecular approximation between residue 10 of secretin and its receptor demonstrated by photoaffinity labeling.
- Possible endogenous agonist mechanism for the activation of secretin family G protein-coupled receptors.
- Differential spatial approximation between secretin and its receptor residues in active and inactive conformations demonstrated by photoaffinity labeling.
- Differential contributions of motilin receptor extracellular domains for peptide and non-peptidyl agonist binding and activity.
- Fluorescence characteristics of hydrophobic partial agonist probes of the cholecystokinin receptor.
- Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma.
- Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor.
- Use of probes with fluorescence indicator distributed throughout the pharmacophore to examine the peptide agonist-binding environment of the family B G protein-coupled...
- Constitutive formation of oligomeric complexes between family B G protein-coupled vasoactive Intestinal polypeptide and secretin receptors.
- Secretin receptors in normal and Diseased human pancreas: marked reduction of receptor binding in ductal neoplasia.
- Insights into interactions between the alpha-helical region of the salmon calcitonin antagonists and the human calcitonin receptor using photoaffinity labeling.
- Insights into the structure and molecular basis of ligand docking to the G protein-coupled secretin receptor using charge-modified amino-terminal agonist probes.
- Differential spatial approximation between cholecystokinin residue 30 and receptor residues in active and inactive conformations.
- Demonstration of a specific site of covalent labeling of the human motilin receptor using a biologically active photolabile motilin analog.
- Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor.
- Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling.
- Paired cysteine mutagenesis to establish the pattern of disulfide bonds in the functional intact secretin receptor.
- Differential effects of modification of membrane cholesterol and sphingolipids on the conformation, function, and trafficking of the G protein-coupled cholecystokinin ...
- Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy.
- Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist.
- Molecular approximation between a residue in the amino-terminal region of calcitonin and the third extracellular loop of the class B G protein-coupled calcitonin recep...
- Suppression of neurite outgrowth by high-dose nerve growth factor is independent of functional p75NTR receptors.
- Spatial approximation between the amino terminus of a peptide agonist and the top of the sixth transmembrane segment of the secretin receptor.
- Importance of the amino terminus in secretin family G protein-coupled receptors. Intrinsic photoaffinity labeling establishes initial docking constraints for the calci...
- Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy tr...
- Heterodimerization of type A and B cholecystokinin receptors enhance signaling and promote cell growth.
- Spatial approximation between two residues in the mid-region of secretin and the amino terminus of its receptor. Incorporation of seven sets of such constraints into a...
Schools
Jefferson Medical College Of Thomas Jefferson University Thomas Jefferson University
Jefferson Med College
Mayo Clinic Rochester
Procedures Preformed
- Endoscopy (Esophagus, Stomach, Small Intestine)
Conditions Treated
- Abdominal Pain
- Anemia
- Cholecystitis and Gallstones
- Diverticulosis, Intestinal
- View All
Doctors Specialties
- Gastroenterology
Accepted Insurances
Awards
- Elected Member
- Super Doctor
Education
-
Mayo School of Graduate Medical Education -
Jefferson Medical College
Hospital
-
Mayo Clinic - Phoenix/Scottsdale, Arizona
Drug Facts
| NPI NUMBER | 1558344390 | |
| NPPES Provider LastName | MILLER | |
| NPPES Provider FirstName | LAURENCE | |
| NPPES Provider ZIPCode | 852595404 | |
| NPPES Provider State | AZ | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 16.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1558344390 |
| Last Name Of The Provider | MILLER |
| First Name Of The Provider | LAURENCE |
| View All |
Similar Doctors
|
|
Dr. Robert G. Leon, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Janet R. Reiser, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anitha D. Yadav, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bradford H. Jones, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew Weinberg, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gustav A. Decker, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gary D. Richey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John R. Harlan, MD |
|
|
Dr. Gavin N. Levinthal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard K. Brooks, MD |
|
|
Dr. Sarah B. Umar, MD
This Doctor is OpenDoctor Recommended.
|